{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "58-year-old male with a right hilar lung occupying lesion found on chest CT on 2019-05-12.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Lung mass",
              "body_part": "Hilar region",
              "modality": "CT",
              "finding": "occupying lesion",
              "date": "2019-05-12"
            }
          ]
        },
        "timestamp": "2019-05-12"
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Biopsy of the right hilar lung lesion revealed adenocarcinoma. Patient has diabetes.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0007097",
              "label": "Adenocarcinoma",
              "status": "active"
            },
            {
              "code": "C0011849",
              "label": "Diabetes Mellitus",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "C0005734",
              "approach": "other",
              "location": "Lung",
              "outcome": "C0007097"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Systemic evaluation revealed pericardial and sacrococcygeal metastases. Next-generation sequencing identified a HER2 mutation (p.Y772_A775dupYVMA) and a BRCA2 germline mutation with PD-L1 (-) and microsatellite stability. Diagnosed with advanced-stage lung adenocarcinoma (cT3N0M1c [pericardial and sacral metastases], stage IVB) with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1. Pericardial effusion was drained.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Lung adenocarcinoma",
              "status": "active",
              "onset_date": null
            }
          ],
          "imaging": [
            {
              "type": "Metastasis",
              "body_part": "Pericardium",
              "modality": "other",
              "finding": "pericardial metastases",
              "impression": "pericardial metastases",
              "date": null
            },
            {
              "type": "Metastasis",
              "body_part": "Sacrococcygeal",
              "modality": "other",
              "finding": "sacrococcygeal metastases",
              "impression": "sacrococcygeal metastases",
              "date": null
            }
          ],
          "procedures": [
            {
              "name": "Pericardiocentesis",
              "approach": "other",
              "date": null,
              "location": "Pericardial space",
              "performed_by": null,
              "outcome": "Drainage of pericardial effusion"
            }
          ],
          "functional_status": [
            {
              "domain": "general",
              "description": "Eastern Cooperative Oncology Group performance status (ECOG PS) of 1",
              "score": "1",
              "scale": "ECOG"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Patient received one cycle of cisplatin, followed by six cycles of first-line chemotherapy (pemetrexed plus cisplatin plus bevacizumab) and four cycles of maintenance therapy, achieving partial response (PR) at each efficacy evaluation. Progression-free survival (PFS) from first-line treatment was 11.3 months.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0008767",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0070601",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0008767",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1441409",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "In May 2020, patient had progressive disease (PD) and received a second-line immuno-chemotherapy regimen (paclitaxel albumin plus pembrolizumab plus bevacizumab), achieving partial response (PR) after two cycles. Paclitaxel albumin was discontinued due to bone pain.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0030393",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2020-05",
              "end_date": null,
              "indication": "C0012634"
            },
            {
              "drug": "C1658905",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2020-05",
              "end_date": null,
              "indication": "C0012634"
            },
            {
              "drug": "C0004944",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2020-05",
              "end_date": null,
              "indication": "C0012634"
            }
          ],
          "diagnoses": [
            {
              "code": "C0012634",
              "label": "Disease Progression",
              "status": "active",
              "onset_date": "2020-05"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "After two cycles of second-line immuno-chemotherapy, new frontal lobe and lung metastases were observed on imaging.",
        "clinical_data": {
          "imaging": [
            {
              "type": "metastasis",
              "body_part": "frontal lobe",
              "modality": "imaging",
              "finding": "new",
              "date": null
            },
            {
              "type": "metastasis",
              "body_part": "lung",
              "modality": "imaging",
              "finding": "new",
              "date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Progression from lung lesion to biopsy revealing adenocarcinoma, patient also has diabetes."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Systemic evaluation revealed pericardial and sacrococcygeal metastases. Next-generation sequencing identified a HER2 mutation (p.Y772_A775dupYVMA) and a BRCA2 germline mutation with PD-L1 (-) and microsatellite stability. Diagnosed with advanced-stage lung adenocarcinoma (cT3N0M1c [pericardial and sacral metastases], stage IVB) with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1. Pericardial effusion was drained.",
        "transition_event": {
          "trigger_type": "interpretation",
          "trigger_entities": [
            "C0007097",
            "C0011849"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Patient received one cycle of cisplatin, followed by six cycles of first-line chemotherapy (pemetrexed plus cisplatin plus bevacizumab) and four cycles of maintenance therapy, achieving partial response (PR) at each efficacy evaluation. Progression-free survival (PFS) from first-line treatment was 11.3 months.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0008767",
            "C0070601",
            "C1441409"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "In May 2020, patient had progressive disease (PD) and received a second-line immuno-chemotherapy regimen (paclitaxel albumin plus pembrolizumab plus bevacizumab), achieving partial response (PR) after two cycles. Paclitaxel albumin was discontinued due to bone pain.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0030393",
            "C1658905",
            "C0004944"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2020-05-01T00:00:00Z"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "After two cycles of second-line immuno-chemotherapy, new frontal lobe and lung metastases were observed on imaging.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [
            "C0027051",
            "C0024077"
          ],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    }
  ]
}